Filtered By:
Specialty: Cancer & Oncology
This page shows you your search results in order of date.
Order by Relevance | Date
Total 129106 results found since Jan 2013.
Glioma Response to IDH Inhibition: Real-World Experience
Clin Cancer Res. 2023 Sep 22. doi: 10.1158/1078-0432.CCR-23-2164. Online ahead of print.ABSTRACTTreatment of IDH mutated non-enhancing grade 2 and 3 diffuse gliomas with ivosidenib leads to reduction of tumor size when assessed via volumetric MRI. IDH inhibition has a therapeutic benefit in patients with these tumors.PMID:37738033 | DOI:10.1158/1078-0432.CCR-23-2164
Source: Clinical Cancer Research - September 22, 2023 Category: Cancer & Oncology Authors: Rimas V Lukas Craig Horbinski Source Type: research
Genetic Predictors of Ibrutinib-Related Cardiovascular Side Effects in Patients with Chronic Lymphocytic Leukemia
CONCLUSIONS: Our findings suggest possible genetic determinants of ibrutinib-related CVSEs in CLL. If replicated in a larger study, pre-treatment pharmacogenetic testing for GATA4 and KCNQ1 polymorphisms may be a useful clinical tool for personalizing treatment selection for CLL and/or instituting early risk-mitigation strategies.PMID:37738027 | DOI:10.1158/1078-0432.CCR-23-0421
Source: Clinical Cancer Research - September 22, 2023 Category: Cancer & Oncology Authors: Issam S Hamadeh Jai N Patel Ryan Jacobs Hang Zeng Jiaxian He Bei Hu Tamara Kay Moyo Amy Soni Steven Park Ed Copelan Belinda Avalos Alicia Hamilton Nury Steuerwald Nilanjan Ghosh Source Type: research
Harnessing Dendritic Cells: Next Frontier for Durable Immune Control in Myeloma
Clin Cancer Res. 2023 Sep 22:OF1-OF3. doi: 10.1158/1078-0432.CCR-23-2292. Online ahead of print.ABSTRACTImmune-based approaches including T-cell redirection have transformed the therapeutic landscape in myeloma. Injection of dendritic cells (DC) led to the induction of immune responses in vaccinated patients with myeloma. These studies pave the way for future combination strategies harnessing DCs to enhance tumor immunity and improve outcomes in myeloma. See related article by Freeman et al., p. 000.PMID:37737650 | DOI:10.1158/1078-0432.CCR-23-2292
Source: Clinical Cancer Research - September 22, 2023 Category: Cancer & Oncology Authors: Madhav V Dhodapkar Source Type: research
Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma
CONCLUSIONS: Two doses of DC:Ad-S, one given immediately before and another after ASCT, were feasible and safe. A high frequency of vaccine-specific immune responses was seen in combination with durable clinical outcomes, supporting ongoing investigation into the potential of this approach.PMID:37735756 | DOI:10.1158/1078-0432.CCR-22-3987
Source: Clinical Cancer Research - September 22, 2023 Category: Cancer & Oncology Authors: Ciara L Freeman Reginald Atkins Indumathy Varadarajan Meghan Menges Jeffrey Edelman Rachid Baz Jason Brayer Omar Castaneda Puglianini Jose Leonel Ochoa-Bayona Taiga Nishihori Kenneth H Shain Bijal Shah Dung Tsa Chen Linda Kelley Domenico Coppola Melissa A Source Type: research
Integrative landscape analysis of prognostic model biomarkers and immunogenomics of disulfidptosis-related genes in breast cancer based on LASSO and WGCNA analyses
CONCLUSION: The risk score model was effective for predicting both prognosis and sensitivity to therapeutic drugs, suggesting its possible usefulness for the management of patients with breast cancer.PMID:37736788 | DOI:10.1007/s00432-023-05372-z
Source: Clinical Breast Cancer - September 22, 2023 Category: Cancer & Oncology Authors: Shuyan Liu Yiwen Zheng Shujin Li Yaoqiang Du Xiaozhen Liu Hongchao Tang Xuli Meng Qinghui Zheng Source Type: research
Initial experience with an electron FLASH research extension (FLEX) for the Clinac system
CONCLUSION: Our studies characterized the non-clinical Clinac-FLEX system as a viable solution to conduct FLASH research that could substantially increase access to ultra-high-dose-rate capabilities for scientists.PMID:37735808 | DOI:10.1002/acm2.14159
Source: Clinical Breast Cancer - September 22, 2023 Category: Cancer & Oncology Authors: Kyuhak Oh Kyle J Gallagher Megan Hyun Diane Schott Sarah Wisnoskie Yu Lei Samuel Hendley Jeffrey Wong Shuo Wang Brendan Graff Christopher Jenkins Frank Rutar Md Ahmed Joshua McNeur Jeffrey Taylor Marty Schmidt Lasitha Senadheera Wendy Smith Donald Umstadt Source Type: research
Proteus mirabilis: A rare cause of pneumonia, radiologically mimicking malignancy of the lung
CONCLUSION: Mass lesions suspected for malignancy should be managed with involvement of multiple medical disciplines, to ensure correct and timely diagnosis. This is to avoid miss-management.PMID:37736480 | PMC:PMC10509339 | DOI:10.1002/ccr3.7937
Source: Clinical Lung Cancer - September 22, 2023 Category: Cancer & Oncology Authors: Saif Ullah Ramin Saadaat Hidayatullah Hamidi Ahmed Maseh Haidary Source Type: research
Non-coding RNAs in cancer immunotherapy: Predictive biomarkers and targets
CONCLUSION: This review summarises important predictive ncRNA biomarkers that were reported in cancer patients treated with different immunotherapeutic modalities, including monoclonal antibodies, small molecule inhibitors, cancer vaccines and CAR-T cells. In addition, a concise discussion on forthcoming perspectives is provided, outlining technical approaches for the optimal utilisation of immunomodulatory ncRNA biomarkers as predictive tools and therapeutic targets.PMID:37735815 | DOI:10.1002/ctm2.1425
Source: Clinical Lung Cancer - September 22, 2023 Category: Cancer & Oncology Authors: Murad Alahdal Eyad Elkord Source Type: research
CT-Guided Percutaneous Cryoablation for Lung Metastasis of Colorectal Cancer: A Case Series
CONCLUSION: Lung CA is a safe and well-tolerated treatment with a satisfactory local control rate for patients with lung metastases derived from mCRC.PMID:37735896 | DOI:10.1177/15330338231201508
Source: Technology in Cancer Research and Treatment - September 22, 2023 Category: Cancer & Oncology Authors: Fu-Ming Wang Rong Luo Jin-Ming Tian Hang Liu Ji-Jin Yang Source Type: research
Integrative landscape analysis of prognostic model biomarkers and immunogenomics of disulfidptosis-related genes in breast cancer based on LASSO and WGCNA analyses
CONCLUSION: The risk score model was effective for predicting both prognosis and sensitivity to therapeutic drugs, suggesting its possible usefulness for the management of patients with breast cancer.PMID:37736788 | DOI:10.1007/s00432-023-05372-z
Source: Clinical Genitourinary Cancer - September 22, 2023 Category: Cancer & Oncology Authors: Shuyan Liu Yiwen Zheng Shujin Li Yaoqiang Du Xiaozhen Liu Hongchao Tang Xuli Meng Qinghui Zheng Source Type: research
Initial experience with an electron FLASH research extension (FLEX) for the Clinac system
CONCLUSION: Our studies characterized the non-clinical Clinac-FLEX system as a viable solution to conduct FLASH research that could substantially increase access to ultra-high-dose-rate capabilities for scientists.PMID:37735808 | DOI:10.1002/acm2.14159
Source: Clinical Genitourinary Cancer - September 22, 2023 Category: Cancer & Oncology Authors: Kyuhak Oh Kyle J Gallagher Megan Hyun Diane Schott Sarah Wisnoskie Yu Lei Samuel Hendley Jeffrey Wong Shuo Wang Brendan Graff Christopher Jenkins Frank Rutar Md Ahmed Joshua McNeur Jeffrey Taylor Marty Schmidt Lasitha Senadheera Wendy Smith Donald Umstadt Source Type: research
Taxane-Based Chemotherapy Is Effective in Metastatic Appendiceal Adenocarcinoma
Oncologist. 2023 Sep 20:oyad263. doi: 10.1093/oncolo/oyad263. Online ahead of print.ABSTRACTAppendiceal cancer is a rare, orphan disease with no therapies currently approved by the FDA for its treatment. Given the limited data regarding drug efficacy, these tumors have historically been treated with chemotherapy designed for colon cancer. However, an overwhelming body of molecular data has demonstrated that appendiceal adenocarcinoma is a distinct entity with key molecular differences from colon cancer, notably rare APC mutation. Recognizing that APC loss-of-function is thought to contribute to taxane resistance and that t...
Source: The Oncologist - September 22, 2023 Category: Cancer & Oncology Authors: Julia Dansby Aditya More Mohammad Zeineddine Abdelrahman Yousef Alisha Bent Farshid Dayyani Robert Wolff Michael Overman John Paul Shen Source Type: research
Looking beyond the surface: Muir Torre syndrome
Arch Clin Cases. 2023 Sep 20;10(3):119-122. doi: 10.22551/2023.40.1003.10255. eCollection 2023.ABSTRACTMuir-Torre Syndrome (MTS) is associated with multiple visceral malignancies. Initial presentation may be a benign skin tumor mimicking a sebaceous cyst. This case report highlights the importance of early diagnosis, genetic testing, and multidisciplinary screening. A 67-year-old man was diagnosed with MTS following excision of a skin lesion (sebaceoma). He was declined both screening colonoscopy and genetic testing. Subsequently, advanced colon cancer was found following presentation with iron deficiency anemia, which ult...
Source: Clinical Colorectal Cancer - September 22, 2023 Category: Cancer & Oncology Authors: Ekta Bagga David Innes Edmund Leung Source Type: research
Non-coding RNAs in cancer immunotherapy: Predictive biomarkers and targets
CONCLUSION: This review summarises important predictive ncRNA biomarkers that were reported in cancer patients treated with different immunotherapeutic modalities, including monoclonal antibodies, small molecule inhibitors, cancer vaccines and CAR-T cells. In addition, a concise discussion on forthcoming perspectives is provided, outlining technical approaches for the optimal utilisation of immunomodulatory ncRNA biomarkers as predictive tools and therapeutic targets.PMID:37735815 | DOI:10.1002/ctm2.1425
Source: Clinical Colorectal Cancer - September 22, 2023 Category: Cancer & Oncology Authors: Murad Alahdal Eyad Elkord Source Type: research
High-Throughput Screening of the Saccharomyces cerevisiae Genome for 2-Amino-3-Methylimidazo 4,5-f Quinoline Resistance Identifies Colon Cancer-Associated Genes
G3 (Bethesda). 2023 Sep 22:jkad219. doi: 10.1093/g3journal/jkad219. Online ahead of print.ABSTRACTHeterocyclic aromatic amines (HAAs) are potent carcinogenic agents found in charred meats and cigarette smoke. However, few eukaryotic resistance genes have been identified. We used Saccharomyces cerevisiae (budding yeast) to identify genes that confer resistance to 2-amino-3-methylimidazo[4,5-f] quinoline (IQ). CYP1A2 and NAT2 activate IQ to become a mutagenic nitrenium compound. Deletion libraries expressing human CYP1A2 and NAT2 or no human genes were exposed to either 400 or 800 µM IQ for five or ten generations. DNA barc...
Source: Cancer Control - September 22, 2023 Category: Cancer & Oncology Authors: Michael Dolan Nick St John Faizan Zaidi Francis Doyle Michael Fasullo Source Type: research
